Jun. 18 at 6:01 AM
$ABCL
Learned that the short interest for
$ABCL
is approximately 20% to 23% of the public float, with about 47.12 million shares sold short. Total float is 300 million shares and over 125 million shares are locked with the top 5 holders ie Carl’s holding company Thermopylae and other institutions. Even if you conservatively add another 25 million shares for other institutions/funds, that leaves an active float of 150 million shares of which 1/3rd is short! What are the shorts expecting for a
$5 and change stock? That it will go to zero? One good update/a positive phase 2 readout in 3 months will create an epic short squeeze. If the readout isn’t great, that doesn’t decimate the company either with several more candidates + more discovery type partnership deals (like the one with Jazz pharma from today morning)
